# Arsenic Trioxide for Structural p53 Mutations

> **NCT04695223** · PHASE2 · UNKNOWN · sponsor: **Shanghai Changzheng Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Arsenic Trioxide
- p53 Mutations
- Refractory Cancer
- Intractable Cancer

## Interventions

- **DRUG:** Arsenic Trioxide

## Key facts

- **NCT ID:** NCT04695223
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04695223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04695223, "Arsenic Trioxide for Structural p53 Mutations". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04695223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*